Skip to content
Peptide research

GHRH

Also known as Growth Hormone-Releasing Hormone · Somatoliberin · GRF
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A 44-amino-acid hormone that triggers pulsatile growth hormone release, marketed via analogs for body composition, recovery, and sleep. The mechanism is well proven, and one analog has solid human trial data for cutting visceral fat, while cognitive benefits have limited controlled human evidence from GHRH analogs and organ-protection claims remain preclinical. Chronic use raises IGF-1 and injection reactions, with an unresolved tumor-growth concern. One formulation is FDA-approved; other products are unregulated.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Physiological stimulation of endogenous GH release in a pulsatile, regulated manner

    Medium

    Native GHRH studies and tesamorelin's FDA label confirm pulsatile, not flat, GH release.

  • Improved body composition (reduced visceral fat) via tesamorelin in HIV lipodystrophy

    High

    Confirmed in phase 3 RCTs and a 2026 meta-analysis; benefit reverses on stopping.

  • Neuroprotective and anti-inflammatory effects in retinal degeneration models

    Low

    Rodent studies only; synthetic analogs protected retinal cells, no human trials exist.

Evidence limits

Evidence Level
Strong Evidence (analogs FDA-approved)

GHRH analogs have a robust clinical evidence base. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy based on Phase 3 trials showing significant reduction in visceral adipose tissue. Sermorelin was FDA-approved for pediatric GH deficiency (now discontinued in US). Clinical trials have also explored GHRH analogs for age-related GH decline, cognitive function in older adults, and sleep improvement. Native GHRH is used clinically as a diagnostic agent for GH deficiency. The overall evidence base for GHRH-system therapeutics is substantial with thousands of human participants across multiple indications.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside a clinical study or an approved pediatric indication; GHRH has been studied in children with GH deficiency.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Injection site reactions (swelling, redness, pain)

    High
  • Elevated IGF-1 levels with chronic use

    High
  • Fluid retention, joint pain, carpal tunnel (GH-related effects)

    Moderate
  • Potential tumor growth stimulation in GH-sensitive cancers

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.